Why GlaxoSmithKline Plc Has Gained 23% Since This Time Last Year

GlaxoSmithKline plc (LON: GSK) has issued a series of resilient statements of late.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has advanced 23% to1,654p during the last 12 months, making the share one of the best performers in the FTSE 100 index.

The global pharmaceutical giant, which employs more than 99,000 people in over 100 countries, seems to have impressed investors with a series of resilient statements — despite the accusations of bribery within its Chinese operation emerging in early July.

Back in February, GlaxoSmithKline announced its 2012 results, which showed a 3% dip in core operating profits to £8,330m.

GSK highlighted that group sales were down by 1% and said that sales at its European operation had slipped 7% — owing to the ongoing economic uncertainty in the eurozone following the financial crisis.

The blue chip also reported that £6.3bn was returned to shareholders over the year — through £2.5bn of share buybacks and by hiking its total dividend 6% to 74p per share.

During April, GlaxoSmithKline issued a first-quarter statement that revealed “sales and earnings in line with our expectations” and “significant pipeline progress”. Group sales were down by 2% for the quarter, as expected, while core earnings per share dropped 6% to 26.9p. The Q1 dividend was increased by 6% to 18p per share.

In addition, the Q1 update disclosed that 2013 expectations for sales growth would be around 1%, and that the restructuring of the group’s European operations was “progressing well”.

Then at the end of July, GlaxoSmithKline disclosed half-year results that showed EPS increasing 4% and a 2% increase in sales.  It also announced that it had received US approval for three new treatments currently in late stage pipeline development. As in Q1, the Q2 dividend was increased by 6% to 18p per share.

Sir Andrew Witty, the chief executive of GlaxoSmithKline, said at the time:

“In the quarter, Group sales grew 2% with growth broadly based across Pharmaceuticals and Vaccines, up 1%, and a continued strong contribution from Consumer Healthcare, up 2% (5% excluding divestments).” 

“European Pharmaceuticals and Vaccines sales were flat, reflecting the annualisation of some government price cuts, but also the early results of our strategy to restructure our European operations …  we remain cautious about the outlook in Europe and expect austerity pressures to continue.”

Going forward, we continue to expect sales to grow broadly across Emerging Markets, we are likely to see some impact to our performance in China as a result of the current investigation, but it is too early to quantify the extent of this.”

The next update from GlaxoSmithKline will be published on 23 October, which may reveal further news that can encourage investors, and how the accusations of bribery within its Chinese operation might play out.

If you already own GlaxoSmithKline shares and are looking for additional blue-chip winners, this exclusive wealth report reviews five particularly attractive FTSE possibilities.

Indeed, all five suggestions offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

> Andrew owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »